A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.

Abstract:

:A dose-response relationship has been suggested for medroxyprogesterone acetate in the treatment of advanced breast cancer. To determine the tolerability and efficacy of increasing doses of megestrol acetate in the treatment of metastatic breast cancer, we conducted a phase I/II study among 57 patients. Three patients each received 480, 800, and 1280 mg/d; 48 patients received 1600 mg/d. Of the 57 patients, 56 patients had had disease progression on prior hormone therapy, chemotherapy, or both. Twenty-seven patients had previously received standard-dose MA (160 mg/d). Among the 37 patients with measurable disease, high-dose megestrol acetate (HDMA) produced 6 (16%) complete responses (CRs) and 6 (16%) partial responses (PRs); 11 patients achieved stable disease (SD). HDMA resulted in improvement or stabilization in 12 of the 20 patients with evaluable, non-measurable disease. There were no responses among the 6 patients with liver metastases. Among the 27 patients who were previously treated with standard-dose MA, including 9 patients with primary treatment failure, HDMA resulted in 1 CR, 3 PRs, and 10 SD. Toxicities, which were mild and reversible, included fluid retention, hypertension, hyperglycemia, and mild congestive heart failure. Two patients had superficial phlebitis. The most profound side effect was weight gain which occurred in 43 patients (75%). This study suggests a dose-response relationship for MA in the treatment of advanced breast cancer. A randomized trial to determine the optimal dose is ongoing.

authors

Parnes HL,Abrams JS,Tchekmedyian NS,Tait N,Aisner J

doi

10.1007/BF01990033

subject

Has Abstract

pub_date

1991-08-01 00:00:00

pages

171-7

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

18

pub_type

临床试验,杂志文章
  • The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer.

    abstract::Sex Hormone-Binding Globulin (SHBG), the plasma carrier for androgens and estradiol, inhibits the estradiol-induced proliferation of breast cancer cells through its membrane receptor, cAMP, and PKA. In addition, the SHBG membrane receptor is preferentially expressed in estrogen-dependent (ER+/PR+) breast cancers which...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006100929670

    authors: Becchis M,Frairia R,Ferrera P,Fazzari A,Ondei S,Alfarano A,Coluccia C,Biglia N,Sismondi P,Fortunati N

    更新日期:1999-03-01 00:00:00

  • Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies.

    abstract::Evidence for an association between fruit and vegetable intake and breast cancer risk is inconclusive. To clarify the association, we conducted a systematic review and meta-analysis of the evidence from prospective studies. We searched PubMed for prospective studies of fruit and vegetable intake and breast cancer risk...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-012-2118-1

    authors: Aune D,Chan DS,Vieira AR,Rosenblatt DA,Vieira R,Greenwood DC,Norat T

    更新日期:2012-07-01 00:00:00

  • Data mining with decision trees for diagnosis of breast tumor in medical ultrasonic images.

    abstract::To increase the ability of ultrasonographic (US) technology for the differential diagnosis of solid breast tumors, we describe a novel computer-aided diagnosis (CADx) system using data mining with decision tree for classification of breast tumor to increase the levels of diagnostic confidence and to provide the immedi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1010676701382

    authors: Kuo WJ,Chang RF,Chen DR,Lee CC

    更新日期:2001-03-01 00:00:00

  • Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis.

    abstract::Triple-negative breast cancer (TNBC) is a subtype of breast tumor with unique characteristics in terms of clinical-pathological presentation, prognosis, and response to therapy. Epidemiological investigations focusing on the identification of risk factors involved in the onset and progression of TNBCs have identified ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-012-2339-3

    authors: Pierobon M,Frankenfeld CL

    更新日期:2013-01-01 00:00:00

  • Is mammographic density differentially associated with breast cancer according to receptor status? A meta-analysis.

    abstract::Mammographic density (MD) is a strong marker of breast cancer risk, but it is debated whether the association holds, and is of a similar magnitude, for different subtypes of breast cancer defined by receptor status or gene expression profiles. A literature search conducted in June 2012 was used to identify all studies...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-012-2362-4

    authors: Antoni S,Sasco AJ,dos Santos Silva I,McCormack V

    更新日期:2013-01-01 00:00:00

  • HER-2/neu expression in primary and metastatic breast cancer.

    abstract::Introduction Trastuzumab is a highly effective therapy for the treatment of HER-2/neu positive breast cancer. To maximize benefit and minimize unnecessary toxicity, patient selection is essential. Currently HER-2/neu analysis is routinely performed only for primary invasive breast cancers, and trastuzumab therapy is r...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-9931-6

    authors: Lower EE,Glass E,Blau R,Harman S

    更新日期:2009-01-01 00:00:00

  • Health disparities in breast cancer: biology meets socioeconomic status.

    abstract::Breast cancer is the most common cancer in women worldwide, accounting for just over 1 million new cases annually. Population-based statistics show that globally, when compared to whites, women of African ancestry (AA) tend to have more aggressive breast cancers that present more frequently as estrogen receptor negati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-010-0827-x

    authors: Dunn BK,Agurs-Collins T,Browne D,Lubet R,Johnson KA

    更新日期:2010-06-01 00:00:00

  • Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.

    abstract::In 1973, McGuire and Chamness (In: O'Malley BW and Means AR (ed) Receptors for Reproductive Hormones, Plenum Press) summarized their work on the estrogen receptor in animal and human breast tumors, and in so doing described a target for therapeutic intervention. At that time there were no clinically useful antiestroge...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00713399

    authors: Jordan VC

    更新日期:1995-01-01 00:00:00

  • Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

    abstract:AIMS:To investigate the efficacy of letrozole 2.5 mg and 10 mg used as primary neoadjuvant therapy for patients with locally advanced and large operable breast cancer. PATIENTS AND METHODS:Twenty-four postmenopausal patients with locally advanced or large operable breast cancer were treated in two consecutive series w...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1010669403283

    authors: Dixon JM,Love CD,Bellamy CO,Cameron DA,Leonard RC,Smith H,Miller WR

    更新日期:2001-04-01 00:00:00

  • High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.

    abstract:PURPOSE:Compared to breast cancer risk genes such as BRCA2, ATM, PALB2, and NBN, no defined phenotype is currently associated with biallelic pathogenic variants (PVs) in CHEK2. This study compared the prevalence of breast and other cancers in women with monoallelic and biallelic CHEK2 PVs. METHODS:CHEK2 PV carriers we...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05543-3

    authors: Rainville I,Hatcher S,Rosenthal E,Larson K,Bernhisel R,Meek S,Gorringe H,Mundt E,Manley S

    更新日期:2020-04-01 00:00:00

  • Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.

    abstract:PURPOSE:The role of sentinel lymph node biopsy (SLNB) in breast cancer patients who undergo neoadjuvant chemotherapy (NAC) remains controversial. This study aims to investigate if axillary lymph node dissection (ALND) could be safely omitted after a negative SLNB in cN1/2 patients who become cN0 after NAC. METHODS:We ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06011-8

    authors: Damin AP,Zancan M,Melo MP,Biazus JV

    更新日期:2020-11-09 00:00:00

  • Notch2 activation is protective against anticancer effects of zerumbone in human breast cancer cells.

    abstract::We showed previously that zerumbone (ZER), a sesquiterpene isolated from subtropical ginger, inhibited in vitro (MCF-7 and MDA-MB-231cells) and in vivo (MDA-MB-231 cells) growth of human breast cancer cells in association with apoptosis induction. Here, we investigated the role of Notch receptors in anticancer effects...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3059-7

    authors: Sehrawat A,Sakao K,Singh SV

    更新日期:2014-08-01 00:00:00

  • Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population.

    abstract:BACKGROUND:Estimating an individual woman's absolute risk for breast cancer is essential for decision making about screening and preventive recommendations. Although the current standard, the Gail model, is well calibrated in populations, it performs poorly for individuals. Mammographic breast density (BD) may improve ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-5152-4

    authors: Tice JA,Cummings SR,Ziv E,Kerlikowske K

    更新日期:2005-11-01 00:00:00

  • Long-term outcome in young women with breast cancer: a population-based study.

    abstract:PURPOSE:Whether young age at diagnosis of breast cancer is an independent risk factor for death remains controversial, and the question whether young age should be considered in treatment decisions is still to be answered. METHODS:From a population-based cohort of 22,017 women with breast cancer, all women <35 years (...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3983-9

    authors: Fredholm H,Magnusson K,Lindström LS,Garmo H,Fält SE,Lindman H,Bergh J,Holmberg L,Pontén F,Frisell J,Fredriksson I

    更新日期:2016-11-01 00:00:00

  • Carotenoids and breast cancer risk: a meta-analysis and meta-regression.

    abstract::The purpose of this article is to comprehensively summarize the associations between carotenoids and breast cancer and quantitatively estimate their dose-response relationships. We searched PubMed, Embase, and Cochrane databases (from January 1982 to 1 May 2011) and the references of the relevant articles in English w...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-011-1723-8

    authors: Hu F,Wang Yi B,Zhang W,Liang J,Lin C,Li D,Wang F,Pang D,Zhao Y

    更新日期:2012-01-01 00:00:00

  • Prognostic factors for patients with breast cancers 1cm and smaller.

    abstract::The widespread use of mammography has resulted in the detection of an increasing number of small invasive breast cancers, i.e. those that are 1cm and smaller. Patients with these small cancers generally have a low incidence of axillary lymph node metastases, and this has led some to question the routine use of axillar...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1006130911110

    authors: Chen YY,Schnitt SJ

    更新日期:1998-01-01 00:00:00

  • Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.

    abstract:PURPOSE:Ki-67 has been clinically validated for risk assessment in breast cancer, but the analytical validation and cutpoint-definition remain a challenge. Intraclass correlation coefficients (ICCs) are a statistical parameter for Ki-67 interobserver performance. However, the maximum degree of variance among pathologis...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05112-9

    authors: Denkert C,Budczies J,Regan MM,Loibl S,Dell'Orto P,von Minckwitz G,Mastropasqua MG,Solbach C,Thürlimann B,Mehta K,Blohmer JU,Colleoni M,Müller V,Klauschen F,Ataseven B,Engels K,Kammler R,Pfitzner BM,Dietel M,Fasching

    更新日期:2019-08-01 00:00:00

  • The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects.

    abstract::Epidemiological studies on the association between SULT1A1 codon 213 polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of the association, a meta-analysis was conducted in this article. Sixteen studies including 9,881 cases and 13,564 controls were collected for SULT1A1...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-010-0953-5

    authors: Sun Y,Zang Z,Xu X,Zhang Z,Zhong L,Zan W,Zhao Y,Sun L

    更新日期:2011-01-01 00:00:00

  • Autoradiographic localization of 3H-ORG 2058, a synthetic progestin, in the mammary glands of the baboon.

    abstract::The uptake and retention of a radiolabeled synthetic progestin ORG 2058 by the mammary glands were examined in the baboon. Four estrogen-primed baboons were injected intravenously with 2.5 micrograms/kg body weight of 3H-ORG 2058. One animal received an additional injection of 2.5 mg/kg body weight of unlabeled proges...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806397

    authors: Weaker FJ,Sheridan PJ

    更新日期:1984-01-01 00:00:00

  • Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.

    abstract::Paclitaxel and vinorelbine are among the most active new agents in metastatic breast cancer. Both in vitro and in vivo studies have shown that the combined administration of these two microtubule-targeting agents is feasible and worthwhile. Based on the promising preclinical data, patients with metastatic breast cance...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1005848921895

    authors: Tortoriello A,Facchini G,Caponigro F,Santangelo M,Benassai G,Persico G,Citarella A,Carola M,Marzano N,Iaffaioli RV

    更新日期:1998-01-01 00:00:00

  • Immunohistochemical and molecular subtypes of breast cancer in Nigeria.

    abstract:OBJECTIVE:Previous studies suggest that the majority of breast cancer in Africans are hormone receptor negative and thus differ from breast cancer in other populations. We decided to evaluate the hormone receptor status of patients seen in our practice to see if they indeed differ from that of other populations. METHO...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9694-5

    authors: Adebamowo CA,Famooto A,Ogundiran TO,Aniagwu T,Nkwodimmah C,Akang EE

    更新日期:2008-07-01 00:00:00

  • Improvement in intramammary sentinel lymph node removal using a novel prototype hand held probe during breast conservative surgery.

    abstract::Intramammary sentinel lymph node excision during breast conservative surgery was performed, in this case report, using a prototype intraoperative gamma probe. In contrast to the four axillary sentinel lymph nodes that were subnormal, the excised intramammary sentinel lymph node was massively invaded by cancer cells. T...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-2128-8

    authors: Mathelin C,Tomasetto C,Rio MC,Chenard MP,Brettes JP,Guyonnet JL

    更新日期:2005-02-01 00:00:00

  • Circulating levels of inflammatory markers and mammographic density among postmenopausal women.

    abstract::Mammographic density is strongly associated with breast cancer risk. Inflammation is involved in breast carcinogenesis, perhaps through effects on mammographic density. We evaluated associations between inflammatory markers interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP) and mammogr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1249-5

    authors: Reeves KW,Weissfeld JL,Modugno F,Diergaarde B

    更新日期:2011-06-01 00:00:00

  • Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.

    abstract::Mucinous breast cancer (MBC) is mainly a disease of postmenopausal women. Pure MBC is rare and augurs a good prognosis. In contrast, MBC mixed with other histological subtypes of invasive disease loses the more favorable prognosis. Because of the relative rarity of pure MBC, little is known about its cell and tumor bi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2377-x

    authors: Jambal P,Badtke MM,Harrell JC,Borges VF,Post MD,Sollender GE,Spillman MA,Horwitz KB,Jacobsen BM

    更新日期:2013-01-01 00:00:00

  • Medical comorbidities predict mortality in women with a history of early stage breast cancer.

    abstract::This analysis was conducted to determine whether comorbid medical conditions predict additional breast cancer events and all-cause mortality in women with a history of early stage breast cancer. Women (n = 2,542) participating in a randomized diet trial completed a self-administered questionnaire regarding whether the...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-010-0732-3

    authors: Patterson RE,Flatt SW,Saquib N,Rock CL,Caan BJ,Parker BA,Laughlin GA,Erickson K,Thomson CA,Bardwell WA,Hajek RA,Pierce JP

    更新日期:2010-08-01 00:00:00

  • Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer.

    abstract::Epidermal growth factor receptor (EGFr) levels were analyzed in 140 primary breast cancer specimens by immunohistochemical assay (ICA), competitive binding assay (BA), or enzyme immunoassay (EIA). Thirty-nine of 118 specimens (33.1%) were scored as positive by ICA, 30 of 116 (25.9%; cut-off level 10 fmol/mg protein) b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00666582

    authors: Iwase H,Kobayashi S,Itoh Y,Kuzushima T,Yamashita H,Iwata H,Naito A,Yamashita T,Itoh K,Masaoka A

    更新日期:1993-12-01 00:00:00

  • BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.

    abstract::The Breast Cancer Family Registry is a resource for interdisciplinary and translational studies of the genetic epidemiology of breast cancer. This resource is available to researchers worldwide for collaborative studies. Herein, we report the results of testing for germline mutations in BRCA1 and BRCA2. We have tested...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0153-8

    authors: Neuhausen SL,Ozcelik H,Southey MC,John EM,Godwin AK,Chung W,Iriondo-Perez J,Miron A,Santella RM,Whittemore A,Andrulis IL,Buys SS,Daly MB,Hopper JL,Seminara D,Senie RT,Terry MB,Breast Cancer Family Registry.

    更新日期:2009-07-01 00:00:00

  • Targeting the EGF receptor in breast cancer treatment.

    abstract::Immunotoxins are a relatively new class of cytotoxic agents consisting of a catalytic toxin linked to an appropriate targeting ligand. The ligand directs the toxin to the surface of a tumor cell, whereupon the toxin enters the cell and catalytically inactivates the ribosome, thus disrupting protein synthesis and effec...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666210

    authors: LeMaistre CF,Meneghetti C,Howes L,Osborne CK

    更新日期:1994-01-01 00:00:00

  • Association of RAD51C germline mutations with breast cancer among Bahamians.

    abstract:PURPOSE:RAD51C is known as an ovarian cancer gene; however, its role in breast cancer susceptibility is less clear. As part of a larger study, we assessed the role of germline RAD51C mutations in breast cancer development. METHODS:We studied 387 unselected, BRCA1- and BRCA2-negative, Bahamian breast cancer cases and 6...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05872-3

    authors: Bagherzadeh M,Szymiczek A,Donenberg T,Butler R,Hurley J,Narod SA,Akbari MR

    更新日期:2020-11-01 00:00:00

  • Whole breast proton irradiation for maximal reduction of heart dose in breast cancer patients.

    abstract:PURPOSE:In left-sided breast cancer radiotherapy, tangential intensity modulated radiotherapy combined with breath-hold enables a dose reduction to the heart and left anterior descending (LAD) coronary artery. Aim of this study was to investigate the added value of intensity modulated proton therapy (IMPT) with regard ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3149-6

    authors: Mast ME,Vredeveld EJ,Credoe HM,van Egmond J,Heijenbrok MW,Hug EB,Kalk P,van Kempen-Harteveld LM,Korevaar EW,van der Laan HP,Langendijk JA,Rozema HJ,Petoukhova AL,Schippers JM,Struikmans H,Maduro JH

    更新日期:2014-11-01 00:00:00